New hope for rare lung cancer: experimental drug combo enters human trials

NCT ID NCT07476287

Recruiting now Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 30, 2026 · Updated 3 times

Summary

This study tests a new medicine called PF-08634404 given with chemotherapy for adults with transformed small cell lung cancer (T-SCLC), a rare and aggressive cancer that develops from another lung cancer type. About 40 participants will receive the drug combo through IV infusions, then continue the study drug alone. The main goal is to see if tumors shrink and to check for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PF-08634404 (also called SSGJ-707) given with chemotherapy
What this could lead to: If it works, this could offer a new treatment option for people with transformed small cell lung cancer, a rare and aggressive cancer that currently has few options.
What could go wrong: This is an early Phase 2 trial with only 40 participants, so results may not apply to everyone. The drug may not shrink tumors or could cause side effects like those from chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung neoplasm small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, SMALL CELL LUNG LUNG NEOPLASMS SMALL CELL CANCER OF THE LUNG SMALL CELL LUNG CANCER SMALL CELL LUNG CANCER ( SCLC ) TRANSFORMED SMALL CELL LUNG CANCER

Contacts and locations

Locations

Centre Léon Bérard
NOT_YET_RECRUITING

Lyon, 69373, France
City of Hope Lennar Foundation Cancer Center
RECRUITING

Irvine, California, 92618, United States
City of Hope National Medical Center
RECRUITING

Duarte, California, 91010, United States
Hope and Healing Clinical Research
RECRUITING

Hinsdale, Illinois, 60521, United States
Hope and Healing Clinical Research
RECRUITING

New Lenox, Illinois, 60451, United States
Hospital São Lucas da PUCRS
RECRUITING

Porto Alegre, 90610-000, Brazil
Hospital Universitario 12 de Octubre
NOT_YET_RECRUITING

Madrid, 28041, Spain
Hospital Universitario Virgen Del Rocio
NOT_YET_RECRUITING

Seville, 41013, Spain
Institut Gustave Roussy
NOT_YET_RECRUITING

Villejuif, VAL DE Marne, 94805, France
Japanese Foundation for Cancer Research
RECRUITING

Kotoku, Tokyo, 135-8550, Japan
Kansai Medical University Hospital
RECRUITING

Hirakata, Osaka, 573-1191, Japan
National Cheng Kung University Hospital
RECRUITING

Tainan, 704302, Taiwan
National Taiwan University Cancer Center (NTUCC)
NOT_YET_RECRUITING

Taipei, 106, Taiwan
National Taiwan University Hospital
RECRUITING

Taipei, 100, Taiwan
Osaka International Cancer Institute(OICI)
RECRUITING

Osaka, 541-8567, Japan
Peking Union Medical College Hospital
RECRUITING

Beijing, Beijing Municipality, 100730, China
Shaare Zedek Medical Center
RECRUITING

Jerusalem, Jerusalem, 9103102, Israel
Shanghai Chest Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200030, China
Sheba Medical Center
RECRUITING

Ramat Gan, HA Merkaz, 5265601, Israel
Taipei Veterans General Hospital
NOT_YET_RECRUITING

Taipei, 11217, Taiwan
Union Hospital Tongji Medical College Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, 430048, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.